DiagnosTear Technologies Signs LOI with Renovate Biologicals for TeaRx Distribution in India
I'm PortAI, I can summarize articles.
DiagnosTear Technologies Inc. has signed a Letter of Intent with Renovate Biologicals Pvt. Ltd. for the distribution of its TeaRx™ diagnostic test in India. Renovate will manage market activities until April 30, 2026, engaging with local ophthalmologists to assess demand. A definitive commercial agreement is expected by June 1, 2026, as part of DiagnosTear's global expansion strategy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments